Jane Street’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-39,560
Closed -$2.67M 8847
2023
Q2
$2.67M Buy
39,560
+39,056
+7,749% +$16.2M ﹤0.01% 3696
2023
Q1
$235K Sell
504
-2,436
-83% -$1.29M ﹤0.01% 7583
2022
Q4
$1.18M Buy
2,940
+1,508
+105% +$578K ﹤0.01% 4724
2022
Q3
$466K Buy
1,432
+908
+173% +$292K ﹤0.01% 6815
2022
Q2
$138K Sell
524
-64
-11% -$16.4K ﹤0.01% 8463
2022
Q1
$177K Sell
588
-36
-6% -$12.5K ﹤0.01% 9114
2021
Q4
$220K Sell
624
-592
-49% -$184K ﹤0.01% 8671
2021
Q3
$311K Sell
1,216
-17,552
-94% -$6.22M ﹤0.01% 8113
2021
Q2
$12.5M Buy
18,768
+18,168
+3,028% +$10.5M ﹤0.01% 1482
2021
Q1
$521K Buy
600
+36
+6% +$38.3K ﹤0.01% 6726
2020
Q4
$523K Buy
564
+72
+15% +$75.7K ﹤0.01% 5669
2020
Q3
$506K Sell
492
-932
-65% -$1M ﹤0.01% 5134
2020
Q2
$1.44M Buy
+1,424
New +$1.32M ﹤0.01% 3527
2020
Q1
Sell
-1,620
Closed -$1.74M 5493
2019
Q4
$1.74M Buy
+1,620
New +$1.65M ﹤0.01% 2103
2018
Q2
Sell
-388
Closed -$448K 5140
2018
Q1
$448K Buy
+388
New +$511K ﹤0.01% 3588

Other funds holding KYNB

Jane Street's KYNB Position: Q1 2026 in Review

Jane Street reduced its Kyntra Bio (KYNB) stake by 2.2% in Q1 2026, selling an estimated $2.1K and leaving 12,228 shares worth $82.9K. The position accounts for ﹤0.01% of the portfolio, ranked #10729.

Jane Street first reported a position in KYNB in Q2 2015 and has held it in 32 quarters since. The position peaked at $8.47M in Q1 2023. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Jane Street held 12,228 shares of Kyntra Bio worth $82.9K as of Q1 2026.
  • Jane Street sold 269 Kyntra Bio shares in Q1 2026, an estimated $2.1K.
  • Kyntra Bio made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10729 holding.
  • Jane Street first reported a position in Kyntra Bio in Q2 2015 and has held it in 32 quarters since.
  • Jane Street's Kyntra Bio position peaked at $8.47M in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.